

South African Dyslipidaemia Guideline Consensus Statement 2018 Update

E Q Klug, F J Raal, A D Marais, C M Smuts, C Schamroth, D Jankelow, D J Blom, D A Webb

Contents

1. Introduction
2. Screening
3. Laboratory investigation of dyslipidaemia
 - 3.1 Initial consultation: Screening and assessment of cardiovascular risk using Framingham tables
 - 3.2 Timing of testing at diagnosis
 - 3.3 Follow-up consultation: Assessing treatment goals and monitoring effectiveness of therapy
 - 3.3.1 Low-density lipoprotein cholesterol (LDL-C)
 - 3.3.2 Full lipogram
 - 3.3.3 Total cholesterol as a surrogate for low-density lipoprotein cholesterol
 - 3.4 Point-of-care finger-prick testing
4. Diagnosis of familial hypercholesterolaemia
5. Secondary causes of dyslipidaemia
6. Cardiovascular risk scoring
 - 6.1 Very high-risk and high-risk individuals do not need to be scored
 - 6.1.1 Other individuals at high risk and very high risk
 - 6.2 How to use the Framingham risk charts
7. Goals of therapy
8. Management of dyslipidaemia
 - 8.1 Lifestyle modification
 - 8.1.1 Nutrition
 - 8.1.2 Dietary fats
 - 8.1.2.1 Unsaturated fats
 - 8.1.2.2 Saturated fats
 - 8.1.2.3 Trans unsaturated fatty acids
 - 8.1.2.4 Dietary cholesterol
 - 8.1.2.5 Supplements
 - 8.1.3 Tobacco smoking and vaping
 - 8.2 Statin therapy
 - 8.2.1 Benefits of statin therapy
 - 8.2.2 Adverse effects of statins
 - 8.2.3 High-dose simvastatin treatment
 - 8.2.4 Scheme for introducing statin treatment
 - 8.3 Ezetimibe
 - 8.4 PCSK9 inhibitors
 - 8.5 Management of hypertriglyceridaemia
 - 8.6 Pharmacotherapy affecting high-density lipoprotein cholesterol
 - 8.7 Bile acid sequestrants
9. Approach to primary prevention
 - 9.1 Lipoprotein(a)
 - 9.2 Lipoprotein particle size
 - 9.3 High sensitivity C-reactive protein
 - 9.4 Coronary artery calcium score
 - 9.5 Carotid ultrasound
10. Special patient populations
 - 10.1 Screening and statin therapy in children younger than 16 years of age
 - 10.2 Young adults
 - 10.3 HIV infection
 - 10.4 The older adult
 - 10.5 Chronic kidney disease
11. Secondary prevention
12. Residual risk

EDITOR

Bridget Farham, BSc Hons, PhD, MB ChB

EDITORS EMERITUS

Daniel J Ncayiyana, MD (Groningen),
FACOG, MD (Hon), FCM (Hon)
JP de V van Niekerk, MD, FRCR
Janet Seggie, BSc (Hons), MD (Birm),
FRCP (Lond), FCP (SA)

ASSOCIATE EDITORS

Q Abdool Karim, A Dhali, R C Pattinson,
A Rothberg, A A Stulting, J Surka, B Taylor,
M Blockman, J M Pettifor, W Edridge,
R P Abratt, D L Clarke

HMPG

ACTING CEO
Dr Manivasan Thandrayen

MANAGING EDITORS

Claudia Naidu
Naadia van der Bergh

TECHNICAL EDITORS

Emma Buchanan
Kirsten Morreira
Paula van der Bijl

PRODUCTION MANAGER

Emma Jane Couzens

SENIOR DESIGNER

Clinton Griffin

CHIEF OPERATING OFFICER

Diane Smith | Tel. 012 481 2069
Email: diances@hmpg.co.za

SALES MANAGER (CAPE TOWN)

Azad Yusuf

JOURNAL ADVERTISING

Reneé Hinze
Ladine van Heerden
Makhadzi Mulaudzi
Charmalin Comalie

ONLINE SUPPORT

Gertrude Fani

FINANCE

Tshepiso Mokoena

HMPG BOARD OF DIRECTORS

Prof. M Lukhele (Chair), Dr M R Abbas,
Dr M Mbokota, Dr G Wolvaardt

ISSN 0256-9574

HMPG website: www.hmpg.co.za

SAMA website: www.samedical.org

Journal website: www.samj.org.za



13. Adherence to therapy
14. Public health
 - 14.1 Dyslipidaemia is a prescribed minimum benefit
 - 14.2 New government treatment recommendations
15. When to refer
16. Conclusions: Implementation of the 2018 guidelines
17. Mechanism of guideline preparation

References

Appendix

List of abbreviations

ACS	acute coronary syndromes
ALT	alanine aminotransferase
ARVs	antiretroviral drugs
BP	blood pressure
CHD	coronary heart disease
CK	creatinase
CKD	chronic kidney disease
CV	cardiovascular
CVD	cardiovascular disease
FH	familial hypercholesterolaemia
GFR	glomerular filtration rate
HDL-C	high-density lipoprotein cholesterol
LDL-C	low-density lipoprotein cholesterol
hsCRP	high-sensitivity C-reactive protein
Lp(a)	lipoprotein(a)
MI	myocardial infarction
RCT	randomised controlled trial
TC	total cholesterol
TG	triglyceride
TLC	therapeutic lifestyle change
ULN	upper limit of normal

ONLINE CONTENTS LISTED IN
 Index Medicus (Medline)
 Excerpta Medica (EMBASE)
 Biological Abstracts (BIOSIS)
 Science Citation Index (SciSearch)
 Directory of Open Access Journals (DOAJ)
 Current Contents/Clinical Medicine

SAMJ SUBSCRIPTION RATES
 Local subscriptions ZAR1 632.00 p.a.
 Foreign subscriptions ZAR3 744.00 p.a.
 Single copies ZAR136.00 local,
 ZAR312.00 foreign

Members of the South African Medical Association receive the SAMJ only on request, as part of their membership benefit.

Subscriptions: Tel. 012 481 2071
 Email: members@samedical.org

The SAMJ is published monthly by the Health and Medical Publishing Group (Pty) Ltd, Co. registration 2004/0220 32/07, a subsidiary of SAMA.

HEAD OFFICE
 Health and Medical Publishing Group (Pty) Ltd
 Block F, Castle Walk Corporate Park,
 Nossob Street, Erasmuskloof Ext. 3,
 Pretoria, 0181
 Tel. 012 481 2069
 Email: dianas@hmpg.co.za

EDITORIAL OFFICE
 Suite 11, Lonsdale Building,
 Lonsdale Way, Pinelands, 7405
 Tel. 021 532 1281 | Cell. 072 635 9825
 Email: publishing@hmpg.co.za

Please submit all letters and articles for publication online at
<http://www.editorialmanager.com/samj>

© Copyright: Health and Medical Publishing Group (Pty) Ltd, a subsidiary of the South African Medical Association

Use of editorial material is subject to the Creative Commons Attribution – Non-commercial Works Licence.
<https://creativecommons.org/licenses/by-nc/4.0>

Printed by TANDYM PRINT

